For advanced lung adenocarcinoma patients with common epidermal growth factor receptor (<i>EGFR</i>) mutations (exon 19 deletions or the exon 21 L858R mutation), tyrosine kinase inhibitors (TKIs) are the standard therapies, and achieve favorable responses. This evidence concerns the gene EGFR and lung adenocarcinoma.